Limits...
Chondroprotective effects of Salubrinal in a mouse model of osteoarthritis.

Hamamura K, Nishimura A, Iino T, Takigawa S, Sudo A, Yokota H - Bone Joint Res (2015)

Bottom Line: Although Guanabenz elevates the phosphorylation level of eIF2α, it did not suppress the progression of OA.Administration of Salubrinal has chondroprotective effects in arthritic joints.Cite this article: Bone Joint Res 2015;4:84-92.

View Article: PubMed Central - PubMed

Affiliation: Indiana University, Purdue University, Indianapolis, 723 West Michigan Street, Indianapolis, Indiana 46202, USA.

No MeSH data available.


Related in: MedlinePlus

Graphs and staining showing the response of human primary chondrocytes to tumour necrosis factoralpha (TNFα) in the presence and absence of Salubrinal (Sal) or Guanabenz (Gu), with a)activation of nuclear factor kappa B (NFκB) by TNFα for 15 minutes and partialdeactivation by Salubrinal, b) matrix metalloproteinase (MMP)13 activity induced by TNFα andsuppressed by 5 µM Salubrinal, c) no detectable effect of Guanabenz on the level of p-NFκBand d) no detectable change of MMP13 activity by Guanabenz shown. CN, vehicle.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4443296&req=5

f1: Graphs and staining showing the response of human primary chondrocytes to tumour necrosis factoralpha (TNFα) in the presence and absence of Salubrinal (Sal) or Guanabenz (Gu), with a)activation of nuclear factor kappa B (NFκB) by TNFα for 15 minutes and partialdeactivation by Salubrinal, b) matrix metalloproteinase (MMP)13 activity induced by TNFα andsuppressed by 5 µM Salubrinal, c) no detectable effect of Guanabenz on the level of p-NFκBand d) no detectable change of MMP13 activity by Guanabenz shown. CN, vehicle.


Chondroprotective effects of Salubrinal in a mouse model of osteoarthritis.

Hamamura K, Nishimura A, Iino T, Takigawa S, Sudo A, Yokota H - Bone Joint Res (2015)

Graphs and staining showing the response of human primary chondrocytes to tumour necrosis factoralpha (TNFα) in the presence and absence of Salubrinal (Sal) or Guanabenz (Gu), with a)activation of nuclear factor kappa B (NFκB) by TNFα for 15 minutes and partialdeactivation by Salubrinal, b) matrix metalloproteinase (MMP)13 activity induced by TNFα andsuppressed by 5 µM Salubrinal, c) no detectable effect of Guanabenz on the level of p-NFκBand d) no detectable change of MMP13 activity by Guanabenz shown. CN, vehicle.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4443296&req=5

f1: Graphs and staining showing the response of human primary chondrocytes to tumour necrosis factoralpha (TNFα) in the presence and absence of Salubrinal (Sal) or Guanabenz (Gu), with a)activation of nuclear factor kappa B (NFκB) by TNFα for 15 minutes and partialdeactivation by Salubrinal, b) matrix metalloproteinase (MMP)13 activity induced by TNFα andsuppressed by 5 µM Salubrinal, c) no detectable effect of Guanabenz on the level of p-NFκBand d) no detectable change of MMP13 activity by Guanabenz shown. CN, vehicle.
Bottom Line: Although Guanabenz elevates the phosphorylation level of eIF2α, it did not suppress the progression of OA.Administration of Salubrinal has chondroprotective effects in arthritic joints.Cite this article: Bone Joint Res 2015;4:84-92.

View Article: PubMed Central - PubMed

Affiliation: Indiana University, Purdue University, Indianapolis, 723 West Michigan Street, Indianapolis, Indiana 46202, USA.

No MeSH data available.


Related in: MedlinePlus